# Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients

> **NCT02698735** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Southern California** · enrollment: 5 (actual)

## Conditions studied

- Recessive Dystrophic Epidermolysis Bullosa

## Interventions

- **DRUG:** Gentamicin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02698735
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-25
- **Primary completion:** 2017-03-31
- **Final completion:** 2017-06-30
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2019-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02698735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02698735, "Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02698735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*